Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Aging Neurosci.

Sec. Parkinson’s Disease and Aging-related Movement Disorders

This article is part of the Research TopicBiomarkers for early detection and progression of Parkinson’s Disease: Integrating genomic, proteomic, imaging, and clinical advancesView all 6 articles

18F-FDG PET/MR reveals specific brain metabolic features in Parkinson's disease with frailty

Provisionally accepted
  • 1shenzhen people'hospital, Shenzhen, China
  • 2United Imaging Healthcare Group Co. Ltd, shanghai, China

The final, formatted version of the article will be published soon.

Background: Frailty is significantly more prevalent in individuals with Parkinson's disease (PD) than in general population,yet the underlying neuropathophysiological mechanisms remain poorly understood. This study aimed to characterize the clinical features and cerebral metabolic patterns of frail PD patients using [¹⁸F]-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET),and to explore the potential pathophysiological mechanisms. Methods: 64 PD patients treated at Shenzhen People's Hospital underwent ¹⁸F-FDG PET/MR imaging during June-December 2024. Age-and sex-matched healthy controls were also recruited (n=17). For PD patients,frailty was assessed using the Fried criteria. Patient demography,cognitive performance,and clinical variables—including UPDRS-III scores—were compared between frail and non-frail PD patients. Regional brain metabolism,measured as ¹⁸F-FDG SUVr,was analyzed in brain regions defined by the Automated Anatomical Labeling (AAL) atlas. Results: Among the PD cohort (mean age: 66.86 ± 6.97 years;30 female),34 were classified as non-frail (mean age: 64.29 ± 6.61 years;16 female) and 30 as frail (mean age: 69.77 ± 6.17 years;14 female). Compared to the non-frail group,frail PD patients were significantly older (P = 0.001) and exhibited more severe motor symptoms (UPDRS-III,P < 0.001;modified Hoehn & Yahr(Modified H&Y) stage,P = 0.028),along with greater cognitive impairment (P < 0.001). Although the daily levodopa equivalent dose did not differ significantly between groups (P = 0.076),a trend toward higher dosage was observed in the frail group. ¹⁸F-FDG PET/MR analysis revealed significantly reduced glucose metabolism in 13 brain regions in frail PD patients compared to non-frail patients. Correlation analyses revealed distinct region-function associations in the cognitive domains of frail PD patients. Regression analysis indicated that hypometabolism in the Temporal_Inf_R was significantly associated with UPDRS-III scores in the frail group. Conclusion: Frailty in PD is associated with advanced age,greater motor severity,and possibly increased medication needs. Frail PD patients exhibit specific patterns of cerebral hypometabolism and more severe cognitive deficits. Distinct brain regions are differentially associated with specific cognitive domains. Notably,reduced metabolism in the Temporal_Inf_R is significantly related to motor symptom severity in frail PD,suggesting a key region in the pathophysiology of frailty in PD.

Keywords: 18F-FDG PET/MR, Frailty, MOCA, Parkinson's disease, UPDRS-III

Received: 07 May 2025; Accepted: 11 Dec 2025.

Copyright: © 2025 LI, Zhang, Mao, Zhao, Zhao, Yang, Sun, Liu, Wang and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Xiangcheng Wang
Xiaoguang Luo

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.